Crescent Biopharma Doses First Patient in ASCEND Trial for Advanced Solid Tumors
Event summary
- First patient dosed in ASCEND Phase 1/2 trial for CR-001, a PD-1 x VEGF bispecific antibody.
- Trial targets advanced solid tumors including NSCLC and gastrointestinal/gynaecological cancers.
- Proof-of-concept data expected in Q1 2027; trial aims to enroll up to 290 patients globally.
- CR-001 combines PD-1 checkpoint inhibition with VEGF blockade for dual anti-tumor effects.
The big picture
Crescent Biopharma’s ASCEND trial marks a critical step in validating its bispecific antibody platform, which aims to combine immune checkpoint inhibition with anti-angiogenic effects. The trial’s global scope and focus on both first-line and previously treated patients reflect the growing emphasis on versatile oncology therapies that can address unmet needs across diverse tumor types.
What we're watching
- Clinical Efficacy
- Whether CR-001 demonstrates superior antitumor activity compared to existing PD-1 inhibitors.
- Combination Potential
- The pace at which Crescent advances ADC combination trials with CR-001, expected in H2 2026.
- Regulatory Pathway
- How proof-of-concept data from ASCEND shapes CR-001’s development strategy across multiple indications.
Related topics